Company intelligence / Profile preview

Refeyn

Oxford, Oxfordshire, United Kingdomrefeyn.com ↗

Ownership: Private
Employees: ~180
Development stage: Commercial

Overview

Refeyn has pioneered mass photometry—a label-free technique for measuring the mass of individual biomolecules in solution. Their instruments are used globally in academic research and biopharma/biotech industry settings to accelerate discovery, drug development, process development, and manufacturing analytics. Over 500 systems have been installed worldwide as of May 2025. The technology has been cited in over a thousand scientific publications. No clinical results apply as the company does not develop therapeutics.

Therapeutic areas: Other
Modalities: DeviceAnalytical Instrument
Industry: Non-Drug Biotech

Partnerships

Collaborates with academic labs (e.g., University of Oxford, University of Copenhagen)Customers include biopharma companies, CDMOs/CROs

Beyond the preview

Go deeper on Refeyn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Refeyn.

Explore the full profile